• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAR
Click for more information
2.17% 23.5¢

PARADIGM BIOPHARMACEUTICALS LIMITED.. - Corporate Spotlight

Market Cap $82.20M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company... Paradigm Biopharmaceuticals Limited is a late-stage drug development company. The Company is engaged in discovering, developing, and delivering pharmaceutical therapies. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
23.5¢ 		Change
0.005(2.17%) 		Mkt cap ! $82.20M
Open High Low Value Volume
23.5¢ 24.0¢ 22.5¢ $186.1K 801.8K

Buyers (Bids)

No. Vol. Price($)
4 33599 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 65498 1
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
23.5¢ 		  Change
0.005 ( 0.00 %)
Open High Low Volume
23.0¢ 24.0¢ 22.0¢ 241967
Last updated 15.48pm 23/08/2024 ?
PAR (ASX) Chart

Top Stories

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

Given the recent fall in iron ore prices below the $100 mark, now might be the time to buy into specialised stocks in the materials sector.
Week 34 Wrap: HotCopper's top watched; Oz banks cut saver interest; Kamala’s 28% corporate tax; AI’s back This week’s biggest story (in my view) for the Australian economy actually started late last week. Quietly, CBA cut its term deposit interest rates, prompting ANZ and NAB to do the same on Monday of this week.
Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt Noronex Limited (ASX:NRX) has kicked off a gravity EM survey at the Damara project in Namibia – part of its earn-in deal with South32.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
IPH raises $100M to buy up Canadian IP firm Bereskin & Parr IPH Ltd has raised $100 million in an institutional placement to support the acquisition, while also launching a share purchase plan.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.